Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series.

Abstract

BACKGROUND:

There is no consensus for the standard treatment of retinal arterial macroaneurysm (RAM). Intravitreal anti-vascular endothelium growth factor (anti-VEGF) is an alternative treatment option for RAM. The purpose of this study is to describe the clinical efficacy of intravitreal ranibizumab or intravitreal conbercept for retinal arterial macroaneurysm.

CASE PRESENTATION:

Three cases that presented with symptomatic RAM were treated with intravitreal anti-VEGF agents. Two eyes received two intravitreal ranibizumab injections with a time interval of one month and completed a one-year follow-up, while one eye only received one intravitreal conbercept injection and was followed up for six months. Both the retinal thickness and the visual acuity were significantly improved at the final clinic visit. The macular hemorrhage and edema were resolved. There were no ocular or systemic side effects.

CONCLUSIONS:

Intravitreal ranibizumab or conbercept might be used as a therapeutic option for symptomatic retinal arterial macroaneurysm patients. Anti-VEGF therapy should be further investigated in a larger series with longer follow-up for this disease profile.

• Authors: Zhongjing Lin, Qiwei Hu, Yanlin Wu, Jianmin Xu, Qiong Zhang
• Journal: BMC ophthalmology (BMC Ophthalmol) Vol. 19 Issue 1 Pg. 18 (Jan 15 2019) ISSN: 1471-2415 [Electronic] England
• PMID: 30646868 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Recombinant Fusion Proteins
• KH902 fusion protein
• Ranibizumab

Topics

• Aged
• Aneurysm (drug therapy)
• Angiogenesis Inhibitors (administration & dosage)
• Female
• Humans
• Intravitreal Injections
• Middle Aged
• Ranibizumab (administration & dosage)
• Recombinant Fusion Proteins (administration & dosage)
• Retinal Diseases (drug therapy)
• Retinal Hemorrhage (drug therapy)